Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS ...Middle East

CARLSBAD, Calif., April 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of a Phase 3 clinical trial of ION363 in patients with amyotrophic lateral sclerosis (ALS) with mutations in the fused in sarcoma gene (FUS). Patients with a mutation...

Hence then, the article about ionis initiates phase 3 trial of novel antisense medicine to treat leading cause of juvenile onset als was published today ( Monday 05/04/2021 - 02:45 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS )

Also on site :

• Union boss ‘held up Communist flag alongside people singing pro-Russia chants in occupied Ukraine’
• Large house fire near Buckeye Lake kills one, critically injures second victim
• 2000s Heavy Metal Band Shares Exciting Music Festival News